Last edition
News about "cosibelimab-ipdl"
Sun Pharma Launches UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma
Sun Pharma has announced the US availability of UNLOXCYT for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation. The updated label includes long-term data supporting durable efficacy and a favourable tolerability profile.
Cosibelimab-ipdl | 16/01/2026 | By News Bureau | 115
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members